New York, May 5, 2026, 3:05 PM EDT
- GeneDx stock plunged roughly 51% following a downward revision to its 2026 revenue forecast.
- Revenue climbed in the first quarter, but still fell short of forecasts, with reimbursement issues and product mix weighing on sales.
- Management is sticking with its full-year adjusted profitability target, though analysts are raising questions around both timing and credibility.
Shares of GeneDx Holdings Corp. fell sharply Tuesday. The genetic testing company slashed its 2026 revenue outlook, overshadowing what had been a strong quarter for test-volume growth and putting fresh pressure on Wall Street’s view of the stock.
The stock slid around 51% to $33.12, knocking the Stamford, Connecticut company’s market cap down to about $970 million. That drop far outpaced losses in bigger diagnostics and genomics players—Natera, Guardant Health, Illumina—suggesting this was a sharp, company-driven selloff, not a sector-wide slump.
No question—doctors are ordering GeneDx tests. The challenge is converting those test orders into the kind of revenue and margins investors want as the company leans hard into whole exome and whole genome sequencing. These tests scan big sections of DNA and are aimed at diagnosing rare diseases.
GeneDx’s first-quarter revenue climbed 17% year over year to $102.3 million, driven partly by a 27% jump in exome and genome test revenue, which hit $90.6 million. Test volume for exome and genome results increased 34% to 27,488. Still, the company ended the quarter with an adjusted net loss of $8.2 million and reported a GAAP net loss totaling $63.3 million.
The company slashed its full-year revenue outlook, now seeing $475 million to $490 million, well below the prior $540 million to $555 million range. Exome and genome revenue growth projections were scaled back too—management now expects at least 20%, down from the earlier 33% to 35% view. The goal for positive adjusted net income this year remains unchanged.
Katherine Stueland, Chief Executive, acknowledged in the company’s statement that GeneDx’s revenue numbers “did not reflect the full potential” of the business. Still, she highlighted a 34% jump in volume as a clear sign of demand. During the call, Stueland said the company made “the right course correction” after taking a close look at its sales channels and product mix. GeneDx, LLC
Chief Financial Officer Kevin Feeley admitted the company’s original outlook was “too aggressive,” attributing the misstep to unexpected speed in mix shift and overestimating contributions from new markets. Feeley said GeneDx faces the task of “rebuild[ing] credibility” by issuing guidance it can actually achieve. The Motley Fool
Reimbursement weighed on results in the near term. According to MarketBeat’s summary, GeneDx reported a blended average reimbursement rate of around $3,300 per test—about $200 short of projections—as outpatient genome testing made up close to 40% of first-quarter outpatient volume. Feeley pointed out that outpatient genome reimbursement ran “about half that of exome,” reflecting lagging payer coverage. MarketBeat
Analyst calls came fast. Kyle Mikson at Canaccord Genuity described the numbers as “alarming,” flagging what he saw as broader issues, Investor’s Business Daily reported, quoting his note. Mikson lowered his price target to $75 from $100, though he maintained the stock was still undervalued. Investors
Keith Hinton, analyst at Freedom Capital Markets, dropped his price target on GeneDx to $93 from $177, citing shaky management credibility and warning that improved outpatient genome reimbursement could be a long wait, maybe years. Hinton told the same report that GeneDx could remain “in the penalty box” until leadership regains trust. Investors
Wells Fargo slashed its price target on GeneDx to $75 from $155 but maintained its Overweight rating, according to TipRanks. The firm pointed to a much softer quarter than anticipated, although exome and genome volumes held up well.
The market’s response reflects worries about balance-sheet health and how well the company can execute. In its 10-Q, GeneDx disclosed an $11.9 million non-cash goodwill impairment linked to Fabric Genomics, plus more impairment charges on Fabric’s intangible assets. This comes after the company slashed its outlook for the unit, citing a shift in commercial strategy and weaker projections for revenue and profit.
GeneDx took out a $100 million term loan from Blackstone in February and reported a $6.6 million loss tied to retiring earlier debt, according to the filing. As of March 31, the company’s cash, cash equivalents, marketable securities, and restricted cash totaled $171.7 million. Another guidance misstep could intensify scrutiny on cash management and how soon adjusted profitability returns.
Management is slashing $25 million from operating expenses, mostly by pulling back on hiring and marketing but aiming to keep key growth efforts intact. For Q2, GeneDx is looking at revenue between $110 million and $112 million, expects to run about 30,000 exome and genome tests, and projects an adjusted net loss near $5 million.
The company insists competitive dynamics haven’t shifted. That could be a plus. Still, after Tuesday’s selloff, investors face the tougher issue: can GeneDx ramp up test volumes and close the reimbursement gap quickly enough to deliver the scale it pledged?
